Rosen Law Firm Urges GeneDx Holdings Corp. (NASDAQ: WGS) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm Urges GeneDx Holdings Corp. (NASDAQ: WGS) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026. GeneDx describes itself as an “American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing and whole exome sequencing for the diagnosis of rare and inherited disorders.”
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that GeneDx Holdings Corp. (NASDAQ: WGS) Misled Investors Regarding its Business Operations.
According to the lawsuit, the claims against defendants arise from their misrepresentations and omissions regarding GeneDx’s statements regarding the impact of Fabric on the overall business of GeneDx. Throughout the Class Period, GeneDx repeatedly made statements that would have caused the average investor to believe that the Fabric acquisition would improve GeneDx’s financials and create efficiencies between it and GeneDx’s core business. These statements include such statements such as: “There is room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric as we lean into the best possible algorithms to optimize dry lab processes.” These and similar statements made throughout the Class Period were false. In truth, defendants knew of, or recklessly disregarded, significant problems in Fabric’s viability that would negatively impact GeneDx’s overall business and operations. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against GeneDx Holdings Corp. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 3, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contacts
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
